These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Immunization with a chimera consisting of the B subunit of Shiga toxin type 2 and brucella lumazine synthase confers total protection against Shiga toxins in mice. Mejias MP; Ghersi G; Craig PO; Panek CA; Bentancor LV; Baschkier A; Goldbaum FA; Zylberman V; Palermo MS J Immunol; 2013 Sep; 191(5):2403-11. PubMed ID: 23918978 [TBL] [Abstract][Full Text] [Related]
25. Ingested Shiga toxin 2 (Stx2) causes histopathological changes in kidney, spleen, and thymus tissues and mortality in mice. Rasooly R; Do PM; Griffey SM; Vilches-Moure JG; Friedman M J Agric Food Chem; 2010 Aug; 58(16):9281-6. PubMed ID: 20681531 [TBL] [Abstract][Full Text] [Related]
26. Combined Action of Shiga Toxin Type 2 and Subtilase Cytotoxin in the Pathogenesis of Hemolytic Uremic Syndrome. Álvarez RS; Gómez FD; Zotta E; Paton AW; Paton JC; Ibarra C; Sacerdoti F; Amaral MM Toxins (Basel); 2021 Jul; 13(8):. PubMed ID: 34437406 [TBL] [Abstract][Full Text] [Related]
27. Large-scale preparation of Shiga toxin 2 in Escherichia coli for toxoid vaccine antigen production. Arimitsu H; Sasaki K; Shimizu T; Tsukamoto K; Shimizu T; Tsuji T Microbiol Immunol; 2013 Jan; 57(1):38-45. PubMed ID: 23157558 [TBL] [Abstract][Full Text] [Related]
28. Activation of the Nlrp3 Inflammasome Contributes to Shiga Toxin-Induced Hemolytic Uremic Syndrome in a Mouse Model. Song L; Xiao Y; Li X; Huang Y; Meng G; Ren Z Front Immunol; 2020; 11():619096. PubMed ID: 33552083 [TBL] [Abstract][Full Text] [Related]
29. The oxidative stress induced in vivo by Shiga toxin-2 contributes to the pathogenicity of haemolytic uraemic syndrome. Gomez SA; Abrey-Recalde MJ; Panek CA; Ferrarotti NF; Repetto MG; Mejías MP; Fernández GC; Vanzulli S; Isturiz MA; Palermo MS Clin Exp Immunol; 2013 Sep; 173(3):463-72. PubMed ID: 23607458 [TBL] [Abstract][Full Text] [Related]
30. Identification of TLR4 as the receptor that recognizes Shiga toxins in human neutrophils. Brigotti M; Carnicelli D; Arfilli V; Tamassia N; Borsetti F; Fabbri E; Tazzari PL; Ricci F; Pagliaro P; Spisni E; Cassatella MA J Immunol; 2013 Nov; 191(9):4748-58. PubMed ID: 24068665 [TBL] [Abstract][Full Text] [Related]
31. Protective role of nitric oxide in mice with Shiga toxin-induced hemolytic uremic syndrome. Dran GI; Fernández GC; Rubel CJ; Bermejo E; Gomez S; Meiss R; Isturiz MA; Palermo MS Kidney Int; 2002 Oct; 62(4):1338-48. PubMed ID: 12234304 [TBL] [Abstract][Full Text] [Related]
32. A potential therapeutic peptide-based neutralizer that potently inhibits Shiga toxin 2 in vitro and in vivo. Li T; Tu W; Liu Y; Zhou P; Cai K; Li Z; Liu X; Ning N; Huang J; Wang S; Huang J; Wang H Sci Rep; 2016 Feb; 6():21837. PubMed ID: 26903273 [TBL] [Abstract][Full Text] [Related]
34. Development of camelid single chain antibodies against Shiga toxin type 2 (Stx2) with therapeutic potential against Hemolytic Uremic Syndrome (HUS). Mejías MP; Hiriart Y; Lauché C; Fernández-Brando RJ; Pardo R; Bruballa A; Ramos MV; Goldbaum FA; Palermo MS; Zylberman V Sci Rep; 2016 Apr; 6():24913. PubMed ID: 27118524 [TBL] [Abstract][Full Text] [Related]
35. New aspects in the pathogenesis of enteropathic hemolytic uremic syndrome. Karch H; Friedrich AW; Gerber A; Zimmerhackl LB; Schmidt MA; Bielaszewska M Semin Thromb Hemost; 2006 Mar; 32(2):105-12. PubMed ID: 16575685 [TBL] [Abstract][Full Text] [Related]
36. Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands. Mulvey GL; Marcato P; Kitov PI; Sadowska J; Bundle DR; Armstrong GD J Infect Dis; 2003 Feb; 187(4):640-9. PubMed ID: 12599081 [TBL] [Abstract][Full Text] [Related]
37. [Cytotoxic effect of Shiga toxin type 2 and its B subunit on human renal tubular epithelial cell cultures]. Creydt VP; Nuñez P; Zotta E; Ibarra C Medicina (B Aires); 2005; 65(2):147-50. PubMed ID: 16075810 [TBL] [Abstract][Full Text] [Related]
38. The Antibiotic Polymyxin B Impairs the Interactions between Shiga Toxins and Human Neutrophils. Carnicelli D; Arfilli V; Ricci F; Velati C; Tazzari PL; Brigotti M J Immunol; 2016 Feb; 196(3):1177-85. PubMed ID: 26695372 [TBL] [Abstract][Full Text] [Related]
39. Characterization of stx2 tubular response in a rat experimental model of hemolytic uremic syndrome. Ochoa F; Lago NR; Gerhardt E; Ibarra C; Zotta E Am J Nephrol; 2010; 32(4):340-6. PubMed ID: 20733289 [TBL] [Abstract][Full Text] [Related]
40. Clinical relevance of shiga toxin concentrations in the blood of patients with hemolytic uremic syndrome. Brigotti M; Tazzari PL; Ravanelli E; Carnicelli D; Rocchi L; Arfilli V; Scavia G; Minelli F; Ricci F; Pagliaro P; Ferretti AV; Pecoraro C; Paglialonga F; Edefonti A; Procaccino MA; Tozzi AE; Caprioli A Pediatr Infect Dis J; 2011 Jun; 30(6):486-90. PubMed ID: 21164386 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]